4Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer[J]. N Engl J Med,2002,346(2) :92.
5Fossella FV, DeVore R, Kerr RN, et al. Randomized phase Ⅲ trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group [J]. J Clin Oncol,2000,18 (12) :2354.
6Hanna N,Shepherd FA,Fossella FV,et al. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy[J]. J Clin Oncol,2004,22(9) :1589.
7Dy GK, Adjei AA. Novel targets for lung cancer therapy: part Ⅰ[J]. J Clin Oncol,2002,20(12) :2881.
8Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor [J]. Clin Cancer Res, 2001,7 (5) :1459.
9Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non- small-cell lung cancer: a phase Ⅲ trial-INTACT 2 [J]. J Clin Oncol,2004,22(5 ) :785.
10Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised,placebo-controlled,muhicentre study (Iressa Survival Evaluation in Lung Cancer ) [ J]. Lancet, 2005,366 (9496) : 1527.
1Buccheri G, Torchio P, Ferrigno D. Clinical equivalence of two cy- tokeratin markers in non-small cell lung cancer: a study of tissue polypeptide antigen and cytokeratin 19 fragments [ J ]. CHEST, 2013,124(2) :622-632.
